{"id":"https://genegraph.clinicalgenome.org/r/1ef1cc2a-b037-4f22-99b2-99f3de389cb2v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1ef1cc2a-b037-4f22-99b2-99f3de389cb2","GCISnapshot":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-02-20T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/86bfdb62-ca03-4f16-8b0c-d662971ba640_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Unpublisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7c9c1fe-d0a8-4cab-9b48-ddfc89d2bbf9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant has a similar effect enzyme folding and assembly that are similar to those for the well-characterized A985G mutation found in approximately 90% of the mutant alleles in patients with MCAD deficiency (OMIM).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa30de05-b8b5-4124-9299-24ffe381931a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7668252","rdfs:label":"Patient 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"cDNAs from patient fibroblasts were PCR amplified and sequenced.","phenotypeFreeText":"Urinary organic acid analysis revealed lactic, glutaric, adipic, octanedioic, decanedioic, and palmitic acid excretion.","phenotypes":["obo:HP_0001943","obo:HP_0000639","obo:HP_0002421","obo:HP_0001638","obo:HP_0001336","obo:HP_0001290","obo:HP_0002240"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f7c9c1fe-d0a8-4cab-9b48-ddfc89d2bbf9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7668252","allele":{"id":"https://genegraph.clinicalgenome.org/r/c137769c-b7c4-4807-b99b-7264168e9858","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"ACADVL, 105-BP DEL","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1621"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3d7ea49b-2ff0-4168-9cea-bc65ba322899_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e89efd33-e605-4512-817f-6c3c8b5f2309","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 26","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: NA, peak CK level: 142,520 uM","phenotypes":["obo:HP_0001254","obo:HP_0001943","obo:HP_0003201"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3d7ea49b-2ff0-4168-9cea-bc65ba322899_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/73ff33f3-1355-4c2a-b59e-4e6c4e48d8a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7224491T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA497694284"}},{"id":"https://genegraph.clinicalgenome.org/r/faa267f2-8808-44ff-870b-c6ffede288b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7224671_7224680dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658655608"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/46fd94c8-9be6-4801-a19e-225ce24314fe_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1efac13b-c3c6-41fe-a0c1-d2aeff45de6b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 20","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 3.7 uM, peak CK level: 50,000 uM","phenotypes":["obo:HP_0011968","obo:HP_0001638","obo:HP_0002789","obo:HP_0002098","obo:HP_0003201","obo:HP_0002045","obo:HP_0001943"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/46fd94c8-9be6-4801-a19e-225ce24314fe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/80fcc11b-2c2b-44a5-8600-22fa6d79fe34","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1078_1182del105","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1622"}},{"id":"https://genegraph.clinicalgenome.org/r/76f3bad7-01cd-4545-8c51-334cff1ccd63","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7220782_7220785del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658655603"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/896c8bfe-3fb7-4ef9-9d6c-703aa7f288ed_proband_score_evidence_line","type":"EvidenceLine","dc:description":"V283A accounts for ~20% of pathogenic alleles (Leslie, 2014). Functional analysis: associated with ~20% residual enzyme activity (Goetzman, 2007; Andresen, 1999).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bcc79e63-a01e-4851-bbe6-1a02efbe58c3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 28","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 2.6 uM, peak CK level: 1000 uM","phenotypes":["obo:HP_0003201","obo:HP_0001824"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/896c8bfe-3fb7-4ef9-9d6c-703aa7f288ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":{"id":"https://genegraph.clinicalgenome.org/r/a20afd87-e79f-443f-a969-14c08fcfe05d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.848T>C (p.Val283Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21025"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7c6aa4a6-b1a2-4882-9a1e-001600f18f2b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"V283A accounts for ~20% of pathogenic alleles (Leslie, 2014). Functional analysis: associated with ~20% residual enzyme activity (Goetzman, 2007; Andresen, 1999). A490P variant  reduces the association of ACADVL with mitochondrial membrane (Goetzman, 2007).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/928aa30b-7358-4f29-8c8c-94e183616859","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8845838","rdfs:label":"Patient 2","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":22,"detectionMethod":"","firstTestingMethod":"PCR","phenotypeFreeText":"Hepatic presentation,VLCAD activity versus palmitoyl-CoA subrate was <10% of control.","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7c6aa4a6-b1a2-4882-9a1e-001600f18f2b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8845838","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f67afb42-b433-4d29-ba85-f65763fbc509","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1468G>C (p.Ala490Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/474888"}},{"id":"https://genegraph.clinicalgenome.org/r/a20afd87-e79f-443f-a969-14c08fcfe05d"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/bf2a212d-a592-4414-a6dc-e445170dc461_proband_score_evidence_line","type":"EvidenceLine","dc:description":"V283A accounts for ~20% of pathogenic alleles (Leslie, 2014). Functional analysis: associated with ~20% residual enzyme activity (Goetzman, 2007; Andresen, 1999).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97dbc044-2659-4ffe-befb-3dc0ac1bc0da","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 22","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 1.2 uM, peak CK level: 2700 uM","phenotypes":"obo:HP_0003201","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/bf2a212d-a592-4414-a6dc-e445170dc461_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/a20afd87-e79f-443f-a969-14c08fcfe05d"},{"id":"https://genegraph.clinicalgenome.org/r/2a5f361b-8dc7-4a64-b9ea-2acf41c30e82","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7223240G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8337982"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/63f94574-6c25-4985-a1ff-543cdf9b4cb9_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6cac7104-9e52-4620-8762-c7548b2e0a50","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 71","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 2.76 uM, peak CK level: 396 uM","phenotypes":"obo:HP_0003236","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/63f94574-6c25-4985-a1ff-543cdf9b4cb9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/5fa9d042-f648-41da-a85b-bb46ed1f5576","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7222744C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8337912"}},{"id":"https://genegraph.clinicalgenome.org/r/7e3713f0-da6e-408e-94b2-644fd6c162f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7221020C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA287435425"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/0ef4bc4d-c22b-4f89-877d-d3fa1cef2630_proband_score_evidence_line","type":"EvidenceLine","dc:description":"R613W variant impacts enzyme activity (Goetzman, 2007).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c707e37f-9703-4556-be28-8bcd5290fede","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8845838","rdfs:label":"Patient 8","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":1,"detectionMethod":"","firstTestingMethod":"PCR","phenotypeFreeText":"VLCAD activity versus palmitoyl-CoA subrate was <10% of control.","phenotypes":"obo:HP_0001644","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/0ef4bc4d-c22b-4f89-877d-d3fa1cef2630_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8845838","allele":[{"id":"https://genegraph.clinicalgenome.org/r/dc1917ff-2cb5-4c23-9f3e-5144862c1d8f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1322G>A (p.Gly441Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21016"}},{"id":"https://genegraph.clinicalgenome.org/r/3aef7df4-a5d8-4b91-905e-011ee126cc3c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1837C>T (p.Arg613Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1623"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/90a44223-1220-442e-9c7d-4b76d7d13eab_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expression of G439D in e. coli demonstrated no enzyme activity (Schiff, 2013).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f8d5b7b-129b-4474-9d13-c15239403717","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 24","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 3.29 uM, peak CK level: 21,000 uM","phenotypes":["obo:HP_0001943","obo:HP_0001987"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/90a44223-1220-442e-9c7d-4b76d7d13eab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/5f9e0153-a247-4b1b-b469-23ba5097a0ab","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1316G>A (p.Gly439Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/203582"}},{"id":"https://genegraph.clinicalgenome.org/r/2f38ef37-ba67-4a10-94a4-3b98f2723ca6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000018.3(ACADVL):c.1328T>G (p.Met443Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/285852"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ccd73c85-0dca-46f5-acea-351b05d69f5b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a71402d-9178-4f11-a526-216ac70aa177","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","rdfs:label":"Case 25","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"46/52 were analyzed for variants in ACADVL. No further information provided on method.","phenotypeFreeText":"C14:1 NBS: 2.83 uM, peak CK level: 40,500 uM","phenotypes":"obo:HP_0003201","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ccd73c85-0dca-46f5-acea-351b05d69f5b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27209629","allele":[{"id":"https://genegraph.clinicalgenome.org/r/80fcc11b-2c2b-44a5-8600-22fa6d79fe34"},{"id":"https://genegraph.clinicalgenome.org/r/1223e738-ea07-446d-8888-783dd27c5918","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.7221626T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA397723180"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98d8fdff-cd92-4074-9033-e70dfa52fab5","type":"EvidenceLine","dc:description":"This study only focused on the cardiac phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57dfc4c5-f81f-4ca6-ae9b-34eb504b3b60","type":"Finding","dc:description":"Patients with VLCADD can present with arrhythmias, before or without significant myocardial dysfunction. Mice deficient for VLCAD showed signs of cardiomyopathy (abnormal myocardial histology and increased susceptibility to arrhythmias).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12893739","rdfs:label":"Exil 2003 Cardiac Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/99ddb21e-b8ce-4829-b922-60a211125b86","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6706b42-b09d-4ed1-8b27-b09b5ee52c66","type":"Finding","dc:description":"Livers of null mice showed mild hepatosteatosis upon fasting. Abnormal acylcarnitine species were predominantly C16 and C18 acylcarnitines. These findings are consistent with biochemical diagnosis of VLCAD deficiency in humans.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11590124","rdfs:label":"VLCAD -/- Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42a46006-47f2-4772-b0c0-ce8fb192ff4b","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9b2e4712-fd42-46bb-8425-fa0a247e5a5f","type":"FunctionalAlteration","dc:description":"Seven of the fibroblast lines had undetectable or trace levels of the enzyme and were further characterized by measuring acyl-coA dehydrogenation activities, palmitic acid oxidation, and VLCAD protein synthesis using pulse-chase.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7769092","rdfs:label":"Aoyama 1995 Patient Cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/130ca053-9f40-4fd5-b89c-b9b374694fda_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/384c43cc-62be-497e-bcf8-a00364ab1504","type":"EvidenceLine","dc:description":"Well-established biochemical function.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6b1b741-785b-4bf1-b754-a8b4960cf174","type":"Finding","dc:description":"Beta-oxidation process involves a series of chain-length-specific enzymes which sequentially remove a molecule of acetyl-CoA per cycle. FAO represents a response to tissue energy depletion when fasting, during illness, and increased activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1730632","rdfs:label":"Izai 1992 Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b62248fd-9d15-4b8c-8b8c-2783f0144d0b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/622ee69e-f205-42a0-8425-0772cc1bf269","type":"Finding","dc:description":"qRT-PCR was used to investigate tissue specific distribution of VLCAD. VLCAD is highly expressed in heart in skeletal muscle, with moderate levels in placenta and pancreas. VLCAD deficiency often manifests with cardiomyopathy and skeletal muscle involvement.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12609736","rdfs:label":"Zhou 2003 Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":547,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/npr2NTew8ek","type":"GeneValidityProposition","disease":"obo:MONDO_0008723","gene":"hgnc:92","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_86bfdb62-ca03-4f16-8b0c-d662971ba640-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}